The maternal drug exposure birth cohort (DEBC) in China.
Humans
Female
Pregnancy
China
/ epidemiology
Maternal Exposure
/ adverse effects
Adult
Premature Birth
/ epidemiology
Pregnancy Trimester, First
Prospective Studies
Pregnancy Outcome
/ epidemiology
Dydrogesterone
/ adverse effects
Progesterone
Birth Cohort
Infant, Newborn
Abortion, Spontaneous
/ epidemiology
Stillbirth
/ epidemiology
Infant, Low Birth Weight
Longitudinal Studies
Incidence
Young Adult
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
21 Jun 2024
21 Jun 2024
Historique:
received:
06
03
2023
accepted:
12
06
2024
medline:
22
6
2024
pubmed:
22
6
2024
entrez:
21
6
2024
Statut:
epublish
Résumé
Drug exposure during pregnancy lacks global fetal safety data. The maternal drug exposure birth cohort (DEBC) study, a prospective longitudinal investigation, aims to explore the correlation of maternal drug exposure during pregnancy with pregnancy outcomes, and establish a human biospecimen biobank. Here we describe the process of establishing DEBC and show that the drug exposure rate in the first trimester of pregnant women in DEBC (n = 112,986) is 30.70%. Among the drugs used, dydrogesterone and progesterone have the highest exposure rates, which are 11.97% and 10.82%, respectively. The overall incidence of adverse pregnancy outcomes is 13.49%. Dydrogesterone exposure during the first trimester is correlated with higher incidences of stillbirth, preterm birth, low birth weight, and birth defects, along with a lower incidence of miscarriage/abortion. Due to the limitations of this cohort study, causative conclusions cannot be drawn. Further follow-up and in-depth data analysis are planned for future studies.
Identifiants
pubmed: 38906856
doi: 10.1038/s41467-024-49623-0
pii: 10.1038/s41467-024-49623-0
doi:
Substances chimiques
Dydrogesterone
90I02KLE8K
Progesterone
4G7DS2Q64Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5312Informations de copyright
© 2024. The Author(s).
Références
McBride, W. Thalidomide and congenital malformations. Lancet 278, 1358 (1961).
Benevent, J., Montastruc, F. & Damase-Michel, C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opin. Drug Saf. 16, 1181–1190 (2017).
pubmed: 28777918
doi: 10.1080/14740338.2017.1363177
Lacroix, I., Damase-Michel, C., Lapeyre-Mestre, M. & Montastruc, J. L. Prescription of drugs during pregnancy in France. Lancet 356, 1735–1736 (2000).
pubmed: 11095263
doi: 10.1016/S0140-6736(00)03209-8
Zhen, J. et al. Specifications for pharmaceutical care in medical institutions. Her. Med. 338, 6–27 (2019).
Yang, Y., Chen, C., & Liu, X. Pharmacokinetics and safety of drugs in mother and fetus during pregnancy. Herb. Med. 36, 5 (2017).
Xia, D. Recommendations on risk control and analysis of the problems existing on labeling contents of medicines used for pregnant and lactating women in package inserts in China. Chin. J. Pharmacovigil. 12, 8 (2015).
Dathe, K. & Schaefer, C. The use of medication in pregnancy. Dtsch. Arztebl. Int. 116, 783–790 (2019).
pubmed: 31920194
pmcid: 6935972
Akhurst, R. J. Taking thalidomide out of rehab. Nat. Med. 16, 370–372 (2010).
pubmed: 20376039
pmcid: 2917634
doi: 10.1038/nm0410-370
Wang, X. et al. Rationales, design and recruitment of the Taizhou Longitudinal Study. BMC Public Health 9, 223 (2009).
pubmed: 19589173
pmcid: 2715397
doi: 10.1186/1471-2458-9-223
Bai, Y. G. et al. The Breast Cancer Cohort Study in Chinese Women: research design and preliminary results of clinical multi-center cohort]. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 41, 2046–2052 (2020).
pubmed: 33378815
Qiu, X. et al. The Born in Guangzhou Cohort Study (BIGCS). Eur. J. Epidemiol. 32, 337–346 (2017).
pubmed: 28321694
doi: 10.1007/s10654-017-0239-x
Zhou, Y. et al. Protocol of a prospective and multicentre China Teratology Birth Cohort (CTBC): association of maternal drug exposure during pregnancy with adverse pregnancy outcomes. BMC Pregnancy Childbirth 21, 593 (2021).
pubmed: 34470618
pmcid: 8411516
doi: 10.1186/s12884-021-04073-0
Hug, L. et al. Global, regional, and national estimates and trends in stillbirths from 2000 to 2019: a systematic assessment. Lancet 398, 772–785 (2021).
pubmed: 34454675
pmcid: 8417352
doi: 10.1016/S0140-6736(21)01112-0
Chawanpaiboon, S. et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob. Health 7, e37–e46 (2019).
pubmed: 30389451
doi: 10.1016/S2214-109X(18)30451-0
Blencowe, H. et al. National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis. Lancet Glob. Health 7, e849–e860 (2019).
pubmed: 31103470
pmcid: 6560046
doi: 10.1016/S2214-109X(18)30565-5
Li, D., Liu, L. & Odouli, R. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage_ population based cohort study. BMJ 327, 368 (2003).
pubmed: 12919986
pmcid: 175811
doi: 10.1136/bmj.327.7411.368
Mitchell, A. A. et al. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am. J. Obstet. Gynecol. 205, 51 e51–51 e58 (2011).
doi: 10.1016/j.ajog.2011.02.029
Eunice Kennedy Shriver National Institute of Child Health and Human Development. Task Force On Research Specific To Pregnant Women And Lactating Women. Available at: https://www.nichd.nih.gov/about/advisory/PRGLAC . (2018). Accessed December 11, 2020.
Araujo, M. et al. Drug prescriptions in French pregnant women between 2015 and 2016: a study in the EGB database. Therapie 76, 239–247 (2021).
pubmed: 32736872
doi: 10.1016/j.therap.2020.07.002
Belleudi, V. et al. The Italian network for monitoring medication use during pregnancy (MoM-Net): experience and perspectives. Front. Pharmacol. 12, 699062 (2021).
pubmed: 34248644
pmcid: 8262612
doi: 10.3389/fphar.2021.699062
Fortinguerra, F. et al. Medication prescriptions before, during and after pregnancy in Italy: a population-based study. Ann. dell’Istituto Super. di sanita 57, 249–258 (2021).
Zhang, J., Ung, C. O. L., Guan, X. & Shi, L. Safety of medication use during pregnancy in mainland China: based on a national health insurance database in 2015. BMC Pregnancy Childbirth 19, 459 (2019).
pubmed: 31795963
pmcid: 6892234
doi: 10.1186/s12884-019-2622-y
Walch, K., Hefler, L. & Nagele, F. Oral dydrogesterone treatment during the first trimester of pregnancy: the prevention of miscarriage study (PROMIS). A double-blind, prospectively randomized, placebo-controlled, parallel group trial. J. Matern. Fetal Neonatal Med. 18, 265–269 (2005).
pubmed: 16318978
doi: 10.1080/14767050500246243
El-Zibdeh M. Randomised clinical trial comparing the efficacy of dydrogesterone, human chorionic gonadotropin (hCG) or no treatment in the reduction of habitual abortion. 10th World Congress on the Menopause. (2002).
Carp, H. A systematic review of dydrogesterone for the treatment of threatened miscarriage. Gynecol. Endocrinol. 28, 983–990 (2012).
pubmed: 22794306
pmcid: 3518297
doi: 10.3109/09513590.2012.702875
Kumar, A., Begum, N., Prasad, S., Aggarwal, S. & Sharma, S. Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial. Fertil. Steril. 102, 1357–1363.e1353 (2014).
pubmed: 25241364
doi: 10.1016/j.fertnstert.2014.07.1251
Queisser-Luft, A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977. Early Hum. Dev. 85, 375–377 (2009).
pubmed: 19193503
doi: 10.1016/j.earlhumdev.2008.12.016
Zaqout, M. et al. The impact of oral intake of dydrogesterone on fetal heart development during early pregnancy. Pediatr. Cardiol. 36, 1483–1488 (2015).
pubmed: 25972284
doi: 10.1007/s00246-015-1190-9
Bartholomeusz, R. K. & Bruce, N. W. Effects of maternal progesterone supplementation of fetal, placental and corpus luteal weights in the rat. Biol. Reprod. 15, 84–89 (1976).
pubmed: 953114
doi: 10.1095/biolreprod15.1.84
Neubert, D. et al. Results of in vivo and in vitro studies for assessing prenatal toxicity. Environ. Health Perspect. 70, 89–103 (1986).
pubmed: 3104025
pmcid: 1474293
doi: 10.1289/ehp.867089
Hendrickx, A. G. et al. Embryotoxicity of sex steroidal hormone combinations in nonhuman primates: I. Norethisterone acetate + ethinylestradiol and progesterone + estradiol benzoate (Macaca mulatta, Macaca fascicularis, and Papio cynocephalus). Teratology 35, 119–127 (1987).
pubmed: 3563930
doi: 10.1002/tera.1420350115
Harlap, S., Prywes, R. & Davies, A. M. Letter: Birth defects and oestrogens and progesterones in pregnancy. Lancet 1, 682–683 (1975).
pubmed: 47104
doi: 10.1016/S0140-6736(75)91784-5
Barr, M. Jr. Birth defects and drugs in pregnancy. O. P. Heinonen, D. Sloan and S. Shapiro. Publishing Sciences Group Inc., Littleton, Massachusetts. 1977. pp. 516 + xi. Teratology 20, 487–488 (1979).
Heinonen, O. P., Slone, D., Monson, R. R., Hook, E. B. & Shapiro, S. Cardiovascular birth defects and antenatal exposure to female sex hormones. N. Engl. J. Med. 296, 67–70 (1977).
pubmed: 830309
doi: 10.1056/NEJM197701132960202
Michaelis, J., Michaelis, H., Gluck, E. & Koller, S. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology 27, 57–64 (1983).
pubmed: 6845218
doi: 10.1002/tera.1420270109
Rock, J. A. et al. Fetal malformations following progesterone therapy during pregnancy: a preliminary report. Fertil. Steril. 44, 17–19 (1985).
pubmed: 4007191
doi: 10.1016/S0015-0282(16)48670-X
Check, J. H., Rankin, A. & Teichman, M. The risk of fetal anomalies as a result of progesterone therapy during pregnancy. Fertil. Steril. 45, 575–577 (1986).
pubmed: 3956772
doi: 10.1016/S0015-0282(16)49292-7
Kallen, B. A. et al. Hormone therapy during pregnancy and isolated hypospadias: an international case-control study. Int. J. Risk Saf. Med. 3, 183–197 (1992).
pubmed: 23511000
doi: 10.3233/JRS-1992-3402
Kallen, B. et al. An international case-control study on hypospadias. The problem with variability and the beauty of diversity. Eur. J. Epidemiol. 8, 256–263 (1992).
pubmed: 1644145
doi: 10.1007/BF00144810
Carmichael, S. L. et al. Maternal progestin intake and risk of hypospadias. Arch. Pediatr. Adolesc. Med. 159, 957–962 (2005).
pubmed: 16203941
doi: 10.1001/archpedi.159.10.957
Ge Guan, Y. L., Rong, C., Jiao, L. & Dong, L. Contraindications analysis of 280 proprietary Chinese medicines for pregnant and lactating women. China Health Ind. 12, 54–58 (2015).
Xiong, Y. et al. The use of Chinese herbal medicines throughout the pregnancy life course and their safety profiles: a population-based cohort study. Am. J. Obstet. Gynecol. MFM 5, 100907 (2023).
pubmed: 36813231
doi: 10.1016/j.ajogmf.2023.100907
Springer, D., Jiskra, J., Limanova, Z., Zima, T. & Potlukova, E. Thyroid in pregnancy: from physiology to screening. Crit. Rev. Clin. Lab. Sci. 54, 102–116 (2017).
pubmed: 28102101
doi: 10.1080/10408363.2016.1269309
Yoshihara, H., Sugiura-Ogasawara, M., Goto, S. & Kitaori, T. Levothyroxine and subclinical hypothyroidism in patients with recurrent pregnancy loss. Am. J. Reprod. Immunol. 85, e13341 (2021).
pubmed: 32894608
doi: 10.1111/aji.13341
van Dijk, M. M. et al. Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 10, 322–329 (2022).
pubmed: 35298917
doi: 10.1016/S2213-8587(22)00045-6
Dhillon-Smith, R. K. et al. Levothyroxine in women with thyroid peroxidase antibodies before conception. N. Engl. J. Med. 380, 1316–1325 (2019).
pubmed: 30907987
doi: 10.1056/NEJMoa1812537
Nazarpour, S., Ramezani Tehrani, F., Amiri, M., Bidhendi Yarandi, R. & Azizi, F. Levothyroxine treatment and pregnancy outcomes in women with subclinical hypothyroidism: a systematic review and meta-analysis. Arch. Gynecol. Obstet. 300, 805–819 (2019).
pubmed: 31399840
doi: 10.1007/s00404-019-05245-2
Dhillon-Smith, R. K. et al. Interventions to prevent miscarriage. Fertil. Steril. 120, 951–954 (2023).
pubmed: 37648141
doi: 10.1016/j.fertnstert.2023.08.955
de Jong, P. G., Kaandorp, S., Di Nisio, M., Goddijn, M. & Middeldorp, S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst. Rev. 2014, Cd004734 (2014).
pubmed: 24995856
pmcid: 6769058
Chinese expert consensus group on prevention and treatment of spontaneous abortion with low molecular weight heparin. Chinese experts consensus on prevention and treatment of spontaneous abortion with low molecular weight heparin. Zhonghua Sheng Zhi Yu Bi Yun Za Zhi 38, 701–708 (2018).
Obstetrics subgroup, Chinese society of obstetrics and gynecology, Chinese medical association, Chinese expert consensus group on diagnosis and management of recurrent spontaneous abortion. Chinese expert consensus on diagnosis and management of recurrent spontaneous abortion (2022). Zhonghua Fu Chan Ke Za Zhi 57, 653–667 (2022).
McClure, E. M. et al. Maternal infection and stillbirth: a review. J. Matern.-Fetal neonatal Med. 35, 4442–4450 (2022).
pubmed: 33233978
doi: 10.1080/14767058.2020.1852206
Goldenberg, R. L., McClure, E. M., Saleem, S. & Reddy, U. M. Infection-related stillbirths. Lancet 375, 1482–1490 (2010).
pubmed: 20223514
pmcid: 3893931
doi: 10.1016/S0140-6736(09)61712-8
Silver, R. K. et al. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am. J. Obstet. Gynecol. 169, 1411–1417 (1993).
pubmed: 8267038
doi: 10.1016/0002-9378(93)90410-K
Cowchock, F. S., Reece, E. A., Balaban, D., Branch, D. W. & Plouffe, L. Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. Am. J. Obstet. Gynecol. 166, 1318–1323 (1992).
pubmed: 1595785
doi: 10.1016/0002-9378(92)91596-3
Palmsten, K. et al. Oral corticosteroids and risk of preterm birth in the california medicaid program. J. Allergy Clin. Immunol. Pract. 9, 375–384.e375 (2021).
pubmed: 32791247
doi: 10.1016/j.jaip.2020.07.047
Palmsten, K. et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology 59, 1262–1271 (2020).
pubmed: 31566229
doi: 10.1093/rheumatology/kez405
Chappell, L. C., Cluver, C. A., Kingdom, J. & Tong, S. Pre-eclampsia. Lancet 398, 341–354 (2021).
pubmed: 34051884
doi: 10.1016/S0140-6736(20)32335-7
Tatum, W. O. Balancing the risks to the fetus from epileptic seizures and antiepileptic drug exposure in pregnancy. Expert Rev. Neurother. 9, 1707–1708 (2009).
pubmed: 19951129
doi: 10.1586/ern.09.124
Gedzelman, E. & Meador, K. J. Antiepileptic drugs in women with epilepsy during pregnancy. Ther. Adv. Drug Saf. 3, 71–87 (2012).
pubmed: 25083227
pmcid: 4110845
doi: 10.1177/2042098611433192